SkinBioTherapeutics PLC (LON:SBTX) CEO Stuart Ashman tells Proactive London's Andrew Scott they're looking at all routes possible to get its psoriasis product into the hands of those that need it as they assesses options for a fast-track human study. It's part of their collaboration with Winclove Probiotics which is well ahead of schedule. Ashman adds that their work with partner Croda to develop an active skincare ingredient is also making good progress.
SkinBioTherapeutics assessing options for a 'rapid trial' of its food supplement
Quick facts: SkinBioTherapeutics PLC
Price: 16.375 GBX
Market Cap: £25.53 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE